RCS - OptiBiotix Health - Investor evening

OptiBiotix HealthAnnouncement

02/05/2019 07:05

RNS Number : 7579X
OptiBiotix Health PLC
02 May 2019
 


OptiBiotix Health plc
("OptiBiotix" or "the Company")
 
Investor evening
 
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announces that Stephen O'Hara, CEO of Optibiotix, will be presenting at an investor evening hosted by Turner Pope Investments Ltd ("TPI") on Monday, 13 May 2019. The event will be held in the City of London and will commence at 5pm.
 
To register your interest and obtain further details, please contact TPI on info@turnerpope.com or call 0203 621 4124.
 
No new material or trading information will be provided.
 
 



OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below














Walbrook PR Ltd


Tel: 020 7933 8780 or optibiotix@walbrookpr.com




Anna Dunphy


Mob: 07876 741 001








 
 
About OptiBiotix Health PLC - www.optibiotix.com  
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human diseases, examples of which include obesity, cholesterol and lipid distribution, diabetes, and skin health.
 
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest, appetite suppression, and skin health. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRASSSFSFFUSELI